3 results about "Cd4 cell" patented technology

HIV-1-related immune activation is not only associated with AIDS progression, but also with CD4+ after cART treatment. + Insufficient T cell recovery is a contributing factor. This invention focuses on nicotinamide adenine dinucleotide (NAD) precursors and their potential in modulating host immune cells against HIV-1. Treatment with nicotinamide mononucleotide (NMN) inhibits HIV-1 infection at the post-transcriptional stage by targeting ACH-2 and primary CD4 cells. + Viral production in T cells. On one hand, the NMN treatment preferentially reduces CD25. + CD4 + Intracellular HIV-1 p24 production in T cells. On the other hand, using in vitro, ex vivo, and in vivo models, NMN consistently inhibited the expression of late T cell activation markers, including CD25 and HLA-DR. Furthermore, NMN works by assisting the production of CD4+. + T-cell regeneration to improve the therapeutic efficacy of cART in HIV-1-infected humanized mice.

The invention provides a CD4 + T monoclonal cell culture medium, a culture method and application of the CD4 + T monoclonal cell culture medium. The culture medium comprises N-acetylcysteine and Trolox. According to the invention, the long-standing technical problem that natural CD4 + T cells are difficult to directly and stably form a monoclonal line is successfully solved. Through a density gradient dilution method and a culture medium formula, the formation of a monoclonal cell line with uniform and stable genetic background by efficient amplification starting from a single CD4 + T cell is realized for the first time. The CD4 + T cell is high in monoclonal formation efficiency and good in monoclonal growth state, and the preparation efficiency of the gene editing cell strain is greatly improved. According to the invention, a cell line with hCCR5-delta 32 CD4 + T cell point mutation is successfully constructed by using a monoclonal cell culture method, and important scientific research reference data is provided for treatment of diseases related to the CCR5 gene.

The invention belongs to the field of medical research, and particularly relates to a method, system and device for evaluating HIV antiviral therapy compliance and a storage medium. The method comprises the following steps: acquiring index data for reflecting ART compliance of an HIV infected person, wherein the index data comprises a nursing retention state, a drug holding rate and a CD4 cell count; constructing a group trajectory model GBTM, and identifying trajectory subgroups of different antiviral treatment compliance in the HIV infected person based on the index data; utilizing a Logistic regression model to evaluate the influence of the demology and ART variable level of different HIV infected persons on the affiliation probability of each trajectory subgroup; utilizing a Cox proportional risk model to evaluate the association between each track subgroup and all-factor death, AIDS death and non-AIDS death; and finally, constructing a dynamic prediction model based on the nursing retention, the drug coverage rate and the CD4 cell counting data by using the combined model, so as to realize real-time early warning of the death risk.